Genomic Valley Biotech

Genomic Valley Biotech Gross Margin

Delisted·Sep 16, 2026

The Gross Margin of Genomic Valley Biotech (539206.BO) as of Oct 16, 2026 is 76.14 %. In the previous year, Gross Margin was 100.00 % — a change of -23.86% (lower).

Gross Margin

76.14 %

YoY

-23.86%

Last updated:

Gross Margin of Genomic Valley Biotech is 2025 76.14 % . Gross Margin of Genomic Valley Biotech was 2024 100.00 % . It decreases by -23.86% lower compared to the previous year.

Genomic Valley Biotech's gross margin stands at 76.1%, down from 97.3% several years earlier.

The Genomic Valley Biotech Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2022
97.25 INR
Jan 1, 2023
41.83 INR
Jan 1, 2024
100.00 INR
Jan 1, 2025
76.14 INR
The Genomic Valley Biotech Gross Margin history
YEARGross MarginYoY
76.14 %-23.86%
100.00 %+139.06%
41.83 %-56.99%
97.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Valley Biotech Stock analysis

What does Genomic Valley Biotech do? Genomic Valley Biotech Ltd, identified by the ticker symbol 539206.BO and the ISIN code INE574D01010, is an Indian corporate entity established within the biotechnology and life sciences sector. The company maintains its primary operational headquarters in Bahadurgarh, a city located in the state of Haryana, India. This geographical positioning places the firm within a significant industrial and technological hub in northern India, facilitating its business operations and strategic partnerships within the regional ecosystem. The organization entered the public equity markets through an Initial Public Offering that was officially executed on July 10, 2015. This milestone marked a critical transition in the company's corporate history, allowing it to raise capital from public investors and increase its visibility within the financial markets. The listing on the Bombay Stock Exchange under the specified ticker provides a mechanism for public trading and valuation of the company's shares. While specific details regarding its industry classification and sector categorization are not explicitly defined in the available reference data, the company's name and operational focus imply a specialization in genomic technologies and biotechnological solutions. The corporate profile is further accessible through its official digital presence at http://www.genomicvalley.com/, where stakeholders and interested parties can obtain additional information regarding its business activities, corporate governance, and financial performance. As a publicly traded entity, Genomic Valley Biotech Ltd is subject to the regulatory frameworks and disclosure requirements mandated by Indian securities regulators. The company's journey from its foundational establishment to its public listing in 2015 represents a structured growth trajectory aimed at expanding its reach and capabilities in the competitive biotech landscape. Investors and analysts monitoring the Indian market may track the company's performance through its stock ticker, utilizing the ISIN for precise identification in global financial databases. The lack of explicit sector or industry tags in the provided data does not diminish the company's operational identity, which remains anchored in the scientific and technological advancements associated with genomics and biotechnology. The headquarters in Bahadurgarh serves as the central node for administrative, research, and strategic decision-making processes, supporting the company's ongoing initiatives and market engagements. Genomic Valley Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Valley Biotech stock

Gross Margin of Genomic Valley Biotech is 76.14 % in 2025.

Gross Margin of Genomic Valley Biotech changed from 100.00 % to 76.14 %, representing a -23.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Genomic Valley Biotech since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Genomic Valley Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genomic Valley Biotech

All Key Metrics — Genomic Valley Biotech